Here are five key notes:
1. In the initial collaboration, Celling’s scientist team will produce research indicating mesenchymal stem cells can be optimized and proliferated when using silicon nitride compared with PEEK and titanium biomaterial standards.
2. A recent in vivo scientific study show Amedica’s proprietary silicon nitride composition outperformed PEEK in attachment testing of mesenchymal stem cells. The implant is designed to plan an active role in implant integration.
3. After the initial testing, Celling will translate the early findings into a clinical trail in spine and orthopedic application to further define silicon nitride’s clinical advantages in combination with cell-based therapies.
4. Amedica CEO Sonny Bal, MD, expects the research to show the favoarable cell adhesion properties of silicon nitride for rapid bone fusion and improved patient outcomes.
5. The intellectual property from both partners could be leveraged in future solutions for nanotechnology.
“As an industry, we continue to strive for innovation beyond current standards and Celling Biosciences has always focused on innovating standards of the future,” said Celling CEO Kevin Bunworth. “Current trends show many evolutions of surface modifications and surface treatments around PEEK and titanium but we believe Amedica’s proprietary technology is the future progression of biologically enhanced implants.”
More articles on orthopedic devices:
Stryker launches Aero-C spinal fusion implant
Nationwide Fund Advisors purchases $26.4M Zimmer Biomet stake
North America dominates global orthopedic prosthetic devices market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
